What is glycopyrrolate?

CUVPOSA is an anticholinergic drug available as an oral solution containing 1 mg glycopyrrolate per 5 mL. The chemical name for glycopyrrolate is pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl) oxy]-1,1-dimethyl-,bromide. The chemical structure is: The empirical formula for CUVPOSA is C 19 H 28 BrNO 3 and the molecular weight is 398.33. The inactive ingredients in CUVPOSA are: citric acid, glycerin, natural and artificial cherry flavor, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium citrate, sorbitol solution, and purified water. Chemical Structure

What kind of drug is glycopyrrolate?

The FDA classifies glycopyrrolate as an anticholinergic. Anticholinergic drugs block acetylcholine, the chemical messenger of the body's "rest and digest" nervous system, by occupying its muscarinic receptors. This eases muscle spasms, dries up secretions, relaxes the bladder and airways, and speeds the heart, depending on the tissue. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

Can you take glycopyrrolate with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run glycopyrrolate against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What brand names is glycopyrrolate sold under?

We track 8 glycopyrrolate-containing products in the U.S.: Seebri Neohaler, Cuvposa, Dartisla ODT, Glycopyrrolate, Glyrx-Pf, Lonhala Magnair Kit, Robinul and Robinul Forte. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

What forms does glycopyrrolate come in?

Across the brands we track, glycopyrrolate is currently marketed as powder, liquid, tablet, orally disintegrating, solution, injectable and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic glycopyrrolate?

Yes. Our catalog lists 1 generic glycopyrrolate product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

Has glycopyrrolate been recalled?

The FDA's Enforcement database lists 2 recall records whose product description mentions glycopyrrolate. The most recent: Glycopyrrolate Oral Solution (Dec 15, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Glycopyrrolate: uses, dosing, side effects & brands

Glycopyrrolate is an anticholinergic sold in the U.S. under 8 brand and generic names, for hyperhidrosis, drug-induced abnormalities and peptic ulcer. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesHow we research

Key facts

Drug class: Anticholinergic
Treats: Hyperhidrosis, Drug-Induced Abnormalities and Peptic Ulcer
Available as: Powder · Liquid · Tablet, orally disintegrating · Solution · Injectable · Tablet
Sold as: 8 products — Seebri Neohaler, Cuvposa and Dartisla ODT, and others
Prescription?: Prescription only
Generic available?: Yes
Typical price: about $0 for a 30-count supply

How glycopyrrolate is dosed

From the FDA label for Cuvposa (application NDA022571). Other glycopyrrolate products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

CUVPOSA must be measured and administered with an accurate measuring device [see Patient Counseling Information (17) ]. Initiate dosing at 0.02 mg/kg orally three times daily and titrate in increments of 0.02 mg/kg every 5-7 days based on therapeutic response and adverse reactions. The maximum recommended dosage is 0.1 mg/kg three times daily not to exceed 1.5-3 mg per dose based upon weight. For greater detail, see Table 1 . During the four-week titration period, dosing can be increased with the recommended dose titration schedule while ensuring that the anticholinergic adverse events are tolerable. Prior to each increase in dose, review the tolerability of the current dose level with the patient's caregiver. CUVPOSA should be dosed at least one hour before or two hours after meals. The presence of high fat food reduces the oral bioavailability of CUVPOSA if taken shortly after a meal [see Clinical Pharmacology (12.3) ]. Table 1: Recommended Dose Titration Schedule (each dose to be given three times daily) Weight Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Dose Level 5 kg lbs (~0.02 mg/kg) (~0.04 mg/kg) (~0.06 mg/kg) (~0.08 mg/kg) (~0.1 mg/kg) 13-17 27-38 0.3 mg 1.5 mL 0.6 mg 3 mL 0.9 mg 4.5 mL 1.2 mg 6 mL 1.5 mg 7.5 mL 18-22 39-49 0.4 mg 2 mL 0.8 mL 4 mL 1.2 mg 6 mL 1.6 mg 8 mL 2.0 mg 10 mL 23-27 50-60 0.5 mg 2.5 mL 1.0 mg 5 mL 1.5 mg 7.5…

Glycopyrrolate side effects

The following serious adverse reactions are described elsewhere in the labeling: Constipation or intestinal pseudo-obstruction [see Warnings and Precautions (5.1) ] Incomplete mechanical intestinal obstruction [see Warnings and Precautions (5.2) ] The most common adverse reactions reported with CUVPOSA are dry mouth, vomiting, constipation, flushing, and nasal congestion. The most common adverse reactions (incidence ≥30%) are dry mouth, vomiting, constipation, flushing, and nasal congestion. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Merz Pharmaceuticals, LLC at 1-844-469-6379 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to CUVPOSA in 151 subjects, including 20 subjects who participated in an 8-week placebo-controlled study (Study 1) and 137 subjects who participated in a 24-week open-label study (six subjects who received CUVPOSA in the placebo-controlled study and 131 new subjects). Table 2 presents adverse reactions reported by ≥ 15% of CUVPOSA-treated subjects from the placebo-controlled clinical trial. Table 2: Adverse…

Every glycopyrrolate product we track (8)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Glycopyrrolate products
#	Drug	Rating	Type	Form	Generic?	Typical price
1	Seebri Neohaler	68/100	Prescription	Powder	Generic	$0	View →
2	Cuvposa	Not yet rated	Prescription	Liquid	Generic	$0

What glycopyrrolate pills look like

Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.

Glycopyrrolate pill imprints
Imprint	Strength	Colour	Shape	Maker
Y;51	2 mg	white	round	—

Combination products containing glycopyrrolate

A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.

Glycopyrrolate recalls

From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.

Frequently asked questions

What is glycopyrrolate?: CUVPOSA is an anticholinergic drug available as an oral solution containing 1 mg glycopyrrolate per 5 mL. The chemical name for glycopyrrolate is pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl) oxy]-1,1-dimethyl-,bromide. The chemical structure is: The empirical formula for CUVPOSA is C 19 H 28 BrNO 3 and the molecular weight is 398.33. The inactive ingredients in CUVPOSA are: citric acid, glycerin, natural and artificial cherry flavor, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium citrate, sorbitol solution, and purified water. Chemical Structure
What kind of drug is glycopyrrolate?: The FDA classifies glycopyrrolate as an anticholinergic. Anticholinergic drugs block acetylcholine, the chemical messenger of the body's "rest and digest" nervous system, by occupying its muscarinic receptors. This eases muscle spasms, dries up secretions, relaxes the bladder and airways, and speeds the heart, depending on the tissue. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take glycopyrrolate with other medicines?: It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run glycopyrrolate against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is glycopyrrolate sold under?: We track 8 glycopyrrolate-containing products in the U.S.: Seebri Neohaler, Cuvposa, Dartisla ODT, Glycopyrrolate, Glyrx-Pf, Lonhala Magnair Kit, Robinul and Robinul Forte. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does glycopyrrolate come in?: Across the brands we track, glycopyrrolate is currently marketed as powder, liquid, tablet, orally disintegrating, solution, injectable and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.